Phase II study of capecitabine and trastuzumab combination chemotherapy in patients with HER2 overexpressing metastatic breast cancers resistant to both anthracyclines and taxanes.

Source:http://linkedlifedata.com/resource/pubmed/id/19082596

Download in:

View as

General Info

PMID
19082596